ArticleCureus2026
Ancillary Diagnostic Utility of Glycoprotein Nonmetastatic Melanoma Protein B (GPNMB) in Diagnostically Challenging Hepatic Angiomyolipoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic angiomyolipoma (HAML) is a rare mesenchymal neoplasm within the perivascular epithelioid cell tumor (PEComa) family that may pose significant diagnostic challenges because of its variable radiologic, histologic, and immunophenotypic features. HAML demonstrates a broad morphologic spectrum, including component-predominant and other uncommon histologic variants, which may obscure the classic triphasic morphology, particularly in limited biopsy specimens. Recently, glycoprotein nonmetastatic melanoma protein B (GPNMB) has emerged as a sensitive immunohistochemical marker for PEComa-family tumors. A 39-year-old man with a history of Hodgkin lymphoma presented with intermittent abdominal pain and an enlarging abdominal mass. Imaging demonstrated a hypervascular fat-containing lesion arising from the left hepatic lobe. Core biopsy revealed a mesenchymal neoplasm composed of mature adipose tissue, epithelioid cells, and thick-walled blood vessels without significant atypia or mitotic activity. Immunohistochemical studies demonstrated focal, patchy positivity for HMB45 and Melan-A; diffuse positivity for GPNMB and smooth muscle actin (SMA); and negativity for HepPar-1, glypican-3, CAM5.2, CK7, S100, and desmin. The morphologic and immunophenotypic findings supported the diagnosis of HAML. The patient subsequently underwent left lateral segmentectomy, and surgical pathology confirmed hepatic angiomyolipoma with negative margins. The postoperative course was uncomplicated. HAML remains a diagnostically challenging hepatic neoplasm because of its broad morphologic spectrum and variable radiologic and immunophenotypic features. Component-predominant and other uncommon variants may complicate recognition of the classic triphasic morphology, particularly in limited biopsy specimens. This case highlights the potential diagnostic utility of GPNMB as an ancillary immunohistochemical marker in challenging HAMLs that demonstrate limited or focal expression of conventional melanocytic markers, such as HMB45 and Melan-A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.